학술논문

Administration of hematopoietic cytokines increases the expression of anti-inflammatory cytokine (IL-10) mRNA in the subacute phase after stroke
Document Type
Report
Source
Neuroscience Research. August, 2007, Vol. 58 Issue 4, p356, 5 p.
Subject
Anti-inflammatory drugs
Messenger RNA
Granulocyte colony-stimulating factor
Cytokines
Stem cells
Transforming growth factors
Neurons
Stroke (Disease)
Language
English
ISSN
0168-0102
Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.neures.2007.04.006 Byline: Yuko Morita (a), Shunya Takizawa (a), Hiroshi Kamiguchi (c), Tsuyoshi Uesugi (a), Hiroshi Kawada (b), Shigeharu Takagi (a) Keywords: G-CSF; SCF; Cytokine; IL-10; Focal ischemia; Neurogenesis Abstract: We investigated the effect of the subcutaneous administration of hematopoietic cytokines, granulocyte colony-stimulating factor (G-CSF)+stem cell factor (SCF), on mRNA expression of tissue cytokines in the acute or subacute phase after focal ischemia in male C57 BL/6J mice. The expression of IL-10 mRNA was elevated at 4-14 days after occlusion when cytokines were given in the acute phase (days 1-10). The expression of IL-10 mRNA was markedly elevated at 14 days after occlusion, then remained high until 28 days when cytokines were given in the subacute phase (days 11-20). However, there were no significant changes in IL-6, TGF-[beta]1, TNF, G-CSF, SCF and iNOS expression following either acute- or subacute-phase treatment. Further, hematopoietic cytokine treatment in the subacute phase, but not in the acute phase, reduced ED1-positive microglia/macrophages in the infarcted brain. Our recent study showed that the subacute-phase treatment is effective for functional recovery, enhancing generation of neuronal cells from both bone-marrow-derived and neural stem/progenitor cells. Taken together, these results suggest that cytokine treatment in the subacute phase may provide a favorable microenvironment for neurogenesis after ischemic stroke through the up-regulation of IL-10. Author Affiliation: (a) Division of Neurology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan (b) Division of Hematology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan (c) Research and Educational Support Center, Tokai University School of Medicine, Isehara, Kanagawa, Japan Article History: Received 21 February 2007; Accepted 12 April 2007